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Despite the reasonably long half-life of immunoglogulin G (IgGs), market pressure for higher
patient convenience while conserving efficacy continues to drive IgG half-life improve-
ment. IgG half-life is dependent on the neonatal Fc receptor (FcRn), which among other
functions, protects IgG from catabolism. FcRn binds the Fc domain of IgG at an acidic pH
ensuring that endocytosed IgG will not be degraded in lysosomal compartments and will
then be released into the bloodstream. Consistent with this mechanism of action, sev-
eral Fc-engineered IgG with increased FcRn affinity and conserved pH dependency were
designed and resulted in longer half-life in vivo in human FcRn-transgenic mice (hFcRn),
cynomolgus monkeys, and recently in healthy humans. These IgG variants were usually
obtained by in silico approaches or directed mutagenesis in the FcRn-binding site. Using
random mutagenesis, combined with a pH-dependent phage display selection process, we
isolated IgG variants with improved FcRn-binding, which exhibited longer in vivo half-life in
hFcRn mice. Interestingly, many mutations enhancing Fc/FcRn interaction were located at
a distance from the FcRn-binding site validating our random molecular approach. Directed
mutagenesis was then applied to generate new variants to further characterize our IgG
variants and the effect of the mutations selected. Since these mutations are distributed
over the whole Fc sequence, binding to other Fc effectors, such as complement C1q
and FcγRs, was dramatically modified, even by mutations distant from these effectors’
binding sites. Hence, we obtained numerous IgG variants with increased FcRn-binding
and different binding patterns to other Fc effectors, including variants without any effector
function, providing distinct “fit-for-purpose” Fc molecules. We therefore provide evidence
that half-life and effector functions should be optimized simultaneously as mutations can
have unexpected effects on all Fc receptors that are critical for IgG therapeutic efficacy.
Keywords: complement C1q, directed mutagenesis, Fc engineering, Fc gamma receptors, FcRn, IgG, random
mutagenesis, therapeutic mAbs
INTRODUCTION
Therapeutic monoclonal antibodies (mAbs) have proven success-
ful in the clinic and are now in widespread use for the treatment of
a variety of diseases including cancer, autoimmune, and infectious
diseases. At the moment, new therapeutic mAbs are undergoing
clinical trials at a record pace constantly filling very dynamic
business pipelines (1). Most therapeutic mAbs are human or
humanized molecules of the immunoglogulin G isotype (IgG),
specifically IgG1, IgG2, and IgG4, which bind with high affinity the
human neonatal Fc receptor (FcRn), in a strictly pH-dependent
Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; ADCP,
antibody-dependent cell-mediated phagocytosis; CDC, complement-dependent
cytotoxicity; FcγR, Fc gamma receptor; FcRn, neonatal Fc receptor; IgG,
immunoglobulin of the G isotype; mAb, monoclonal antibody; NK, natural killer;
PK, pharmacokinetics; SPR, surface plasmon resonance; WT, wild-type.
manner. This Fc/FcRn binding is largely responsible for the long
half-life of IgGs as FcRn prevents IgG intracellular degradation.
Following pinocytosis, IgGs are internalized into the endosomes
of cells where the low pH (pH 5–6) promotes binding to FcRn
with nanomolar affinity. Bound IgG-Fc/FcRn complexes are recy-
cled back to the cell surface and dissociate at the neutral pH of the
extracellular fluid, returning thus to the blood circulation. Due
to the same mechanism, FcRn is also involved in IgG transport
across placental, fetomaternal, and polarized cellular barriers (2,
3). This property has been successfully exploited for pulmonary
delivery and intranasal immunization with Fc-fusion proteins (4,
5). Recently, FcRn was shown to enable transepithelial transport
of Fc-targeted nanoparticles delivered orally in mice. This innov-
ative study paves the way for potential oral administration to treat
chronic diseases (6). FcRn properties in transport and catabolism
mainly occur in endothelial and epithelial cells. In human, FcRn
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is also expressed by many immune cells such as macrophages,
monocytes, and dendritic cells. Several recent studies demon-
strated unexpected roles for FcRn in antigen presentation (7–9)
and phagocytosis (10) revealing a wide range of functions for
this receptor in immunological and non-immunological mecha-
nisms. A fundamental understanding of FcRn’s versatile roles will
be essential to guide the development of therapeutic mAbs- and
Fc-fusion proteins (11), especially when engineering Fc variants
with modulated FcRn binding (12).
Given the considerable role of FcRn in antibody homeostasis,
the IgG–Fc/FcRn interaction has been extensively studied for the
last 20 years by directed mutagenesis (13) and crystallography (14).
The FcRn-binding site is structurally conserved among species and
is localized in the CH2/CH3 interdomain Fc region. Based on this
knowledge, Fc-engineered mAbs with increased FcRn affinity and
conserved pH dependency were obtained by alanine scanning (13),
directed mutagenesis (15), and in silico approach (16–18) focused
on the FcRn-binding site. The resulting Fc variants usually include
two to three substitutions in or close to the FcRn-binding site.
Consistent with FcRn’s role in IgG catabolism, such engineered
mAbs showed longer half-life in vivo in human FcRn-transgenic
mice (hFcRn mice) and/or cynomolgus monkeys (16–24). For
instance, Fc variants of the anti-VEGF bevacizumab and the anti-
EGFR cetuximab (Fc-LS, M428L/N434S) demonstrated half-lives
extended up to almost fivefold in hFcRn mice and threefold in
cynomolgus monkeys (18). When introduced in a CTLA4-Fc-
fusion protein, this Fc-LS variant exhibited increased half-life in
cynomolgus monkeys as well, albeit at a lower level than for mAbs
(1.4-fold increase) (25). Remarkably, for the first time in healthy
humans an Fc-engineered anti-RSV mAb (motavizumab-YTE,
M252Y/S254T/T256E) showed a significant serum half-life exten-
sion (up to 100 days, two- to fourfold increase), fully confirming
in humans the results previously obtained in animal models (19,
26). This proof of concept validated for the first time in humans
the usefulness of increasing FcRn binding to obtain mAbs with
extended half-life. Such improved therapeutic mAbs should prove
attractive for developers as they offer several advantages allowing
a positive differentiation from the competition. First, treatment
intervals could be increased while keeping the same dosing, result-
ing in better patient convenience and reduced costs. Second, for the
same efficacy, with the same dosing interval, drug quantities may
be lowered, reducing costs as well. Finally, the use of the same dose
and dosing interval as the parent antibody should result in higher
drug exposure. Interestingly, when this setting was used, greater
anti-tumor activity was observed for the Fc-LS variants tested in
hFcRn/Rag1−/− tumor xenografted mice, showing a positive cor-
relation between FcRn-binding enhancement and in vivo efficacy
(18). Whether this improved therapeutic efficacy is solely due to
prolonged drug exposure, or also due to other FcRn-mediated
mechanisms, needs to be elucidated.
On the other hand, it is now clearly established that the thera-
peutic efficacy of mAbs substantially rely on their ability to engage
the immune system via their Fc domain (27). This Fc-dependent
engagement is mainly mediated by crosslinking of Fcγ recep-
tors (FcγRs) widely expressed on many innate immune effector
cells such as NK cells, monocytes, macrophages, and neutrophils.
Immune effector cells express one or more activating FcγRs, FcγRI
(CD64), FcγRIIA (CD32a), and FcγRIIIA (CD16a), and/or the
only inhibitory receptor FcγRIIB (CD32b). Following engage-
ment of their activating FcγRs, these cells kill tumor or infected
cells through antibody-dependent cellular cytotoxicity (ADCC)
or phagocytosis (ADCP). Natural polymorphisms of these FcγRs
have been described in humans, resulting in modulated affinities
for IgG subclasses. These FcγRs polymorphisms, especially the
FcγRIIIA polymorphism (V/F158), influence patients’ response
to treatment with therapeutic mAbs (28). More favorable clini-
cal responses were indeed observed in patients homozygous for
the higher-affinity allele of FcγRIIIA (V158) in various disorders:
with the anti-CD20 rituximab in non-Hodgkin lymphomas (29),
in immune thrombocytopenia (30), and in rheumatoid arthritis
(31), with the anti-HER2 trastuzumab in metastatic breast can-
cer (32), with the anti-EGFR cetuximab in metastatic colorectal
cancer (33), and with the anti-TNFα infliximab in Crohn’s dis-
ease (34). These findings suggest a crucial role for FcγRIIIA in
the in vivo activity of therapeutic mAbs because the V158 poly-
morphic variant displays a higher affinity for IgG1 and increased
ADCC. Therefore, in order to enhance therapeutic activity, many
protein-Fc-engineered mAbs with increased FcγRIIIA binding
were designed (35) using alanine scanning (13, 36), random muta-
genesis (37), and in silico approach (38). Glyco-engineering was
also successfully used to that aim, as Fc glycan content strongly
influences Fc/FcγRIIIA interaction, contrarily to the Fc/FcRn
interaction, which is not dependent on the glycan structure. The
absence of fucose residues on the Fc glycan moiety of mAbs has
long been associated with increased affinity for FcγRIIIA (39).
Afucosylated or low fucosylated mAbs with strongly enhanced
cytotoxicity were obtained by cellular engineering. More than 20
glyco-engineered mAbs, with higher ADCC, are now in clinical
studies and two have already been approved since 2012 (moga-
mulizumab and obinutuzumab) confirming the success of this
approach (40).
In a previous study, we demonstrated that glyco-engineering
to improve cytotoxicity and protein-Fc engineering to increase
half-life can be combined to further optimize therapeutic mAbs
(41). In our approach, we used a random mutagenesis technology
with a pH-dependent phage display selection process to isolate
several Fc variants of human IgG1 with improved FcRn affinity.
Interestingly, some of the identified mutations, enhancing Fc/FcRn
interaction, were located at a distance from the FcRn-binding site
validating our random molecular approach. When produced as
low fucosylated molecules (EMABling® platform), our IgG vari-
ants demonstrated increased serum persistence in hFcRn mice
(half-life of 23 h for the IgG-WT and 64 h for our best IgG vari-
ant) as well as conserved enhanced ADCC for five out of our six
best variants. In this study, we used directed mutagenesis to fur-
ther characterize the effect of the mutations previously selected on
the Fc/FcRn interaction. Because these mutations are distributed
on the whole Fc sequence, we assessed the binding of several Fc
variants to the complement C1q and FcγRs, and evaluated effec-
tors functions, ADCC and CDC, as well. We therefore obtained
numerous IgG variants with increased FcRn binding and different
binding patterns to other Fc receptors and C1q, including variants
without any effector function, providing distinct “fit-for-purpose”
Fc molecules.
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MATERIALS AND METHODS
EXPRESSION AND PURIFICATION OF HUMAN FcRn
Soluble human FcRn was produced by GTP Technology using
the baculovirus expression system as previously described (42).
The α-chain cDNA encoding the leader peptide and extracellu-
lar domains (codons 1–290) was tagged with a TEV sequence
and a 6× polyhistidine tag. The derivative α-chain and the β2-
microglobulin chain were cloned into pFastBacDual under the P10
and polyhedrine promoters, respectively. A fusion protein contain-
ing the β2-microglobulin chain and theα-chain fused to the amino
terminal part of the bacteriophage p3 protein and the CVDE pro-
tein (FcRn-p3) was also produced. Proteins with more than 90%
purity were obtained after IgG-Sepharose and IMAC purification
steps.
PHAGE-ELISA ASSAYS OF Fc VARIANTS
The human Fc gene encoding amino acid residues 226–447 [EU
index as in Kabat (43) and Supplementary Material], derived
from a human IgG1 heavy chain (G1m1, 17 allotype), was
cloned into the phagemid vector pMG58 (pMG58-Fc226) as a
BamHI/EcoRI fragment using standard PCR protocols. Wild-type
Fc (Fc-WT) and variants were expressed on the surface of the
bacteriophage M13 (41, 44) and their FcRn-binding character-
istics were determined using an ELISA test at pH 6.0. Briefly,
E. coli XL1-Blue bacteria containing the Fc variants (in pMG58
vector) were grown as separate clones on a 96-well plate in
800µl cultures in 2YT medium supplemented with 100µg/ml
ampicillin, 15µg/ml tetracycline, and 1% (w/v) glucose at 30°C,
230 rpm until OD600nm= 0.6 is reached. Cells were then infected
with M13 helper phage (M13KO7, New England Biolabs, ratio
bacteria/phage= 1/3) at 37°C for 20 min. Phage-Fc were pro-
duced overnight at 26°C, 230 rpm in 2YT/ampicillin/glucose with
0.5 mM IPTG and 30µg/ml kanamycin and recovered in the super-
natants after centrifugation for 30 min. at 3,000× g. These super-
natants were directly diluted (1/2 and 1/4) in phosphate buffer pH
6.0 (100 mM sodium phosphate, 50 mM sodium chloride pH 6.0,
called P6), supplemented with 5% skimmed milk and 0.1%Tween-
20, and tested on Maxisorp immunoplates previously coated with
0.25µg FcRn-p3/well and blocked with 5% skimmed milk in P6.
After incubation for 2 h at 37°C, wells were washed three times
with P6/0.1% Tween-20 and bound phages were detected with an
HRP anti-M13 antibody (GE Healthcare).
DIRECTED MUTAGENESIS
Directed mutagenesis was performed to construct positive controls
and remove or add point mutations by overlap PCR using stan-
dard protocols. All the variants were constructed with overlapping
primers containing the desired mutations and the primers MG-
619 (5′-AGTACTGACTCTACCTAGGATCCTGCCCACCGTGC-
3′) and MG-621 (5′-ACTGCTCGATGTCCGTACTATGCGGCCG
CGAATTC-3′) for cloning (BamHI and EcoRI restriction sites
are underlined and italic characters correspond to non-specific
tails). All the variants constructed by directed mutagenesis
are described in patent applications WO2010106180 (45) and
WO2012175751 (46). The positive controls for FcRn were the
double variant T250Q/M428L (16, 17) (Fc-QL), the triple vari-
ant M252Y/S254T/T256E (15) (Fc-YTE), and the double variant
M428L/N434S (Fc-LS) (18). The positive control for FcγRIIIA was
S239D/I332E (C1) (38), for the complement C1q; K326W/E333S
(C3) (47), for FcγRIIA; G236A (C4) (48), and for FcγRIIB;
S267E/L328F (C5) (49).
PRODUCTION OF IgG VARIANTS IN YB2/0 CELLS
The Fc WT and variants were produced in IgG format with an
anti-CD20 specificity based on the Fv domain of CAT 13.6E12
(50), using the YB2/0 cell line (ATCC, CRL-1662). Heavy and light
chains of the anti-CD20 antibody were cloned into the CHK622-
08 vector, optimized for production in Y2B/0 cells, as previously
described (41). Each linearized expression construct was intro-
duced by electroporation into 5× 106 YB2/0 cells. Cells were then
expanded to 25,000 cells/ml in RPMI 1640 medium+ 5% v/v
dialyzed FCS (Invitrogen) and dispensed in 1 ml/well into 24-
well plates. After 3 days, selection pressure was applied by adding
geneticin (Invitrogen) and methotrexate (Sigma) to obtain final
concentrations of 0.5 g/l and 25 mM respectively, in 2 ml/well.
After 11 days, resistant cells were pooled for each construct and
progressively expanded with DMEM medium+ 5% v/v Ultra-low
IgG FCS (Invitrogen) until two 2 l-roller bottles, each contain-
ing 0.9 l of cell suspension can be incubated at 2 rpm. Cells
were allowed to grow and die (4–5 days) before supernatant
collection, clarification by low-speed centrifugation and volume
reduction by ultra-filtration using a Pellicon XL Filter (Milli-
pore). The concentrated culture supernatants were injected into
a HiTrap protein A FF column (GE Healthcare). Bound antibod-
ies were eluted with 0.1 M sodium citrate, pH 3.0, and fractions
were neutralized using 100µl of 1 M Tris–HCl pH 7.5/ml of
elution buffer. Fractions containing the antibodies were pooled
and dialyzed against PBS pH 6.0, and the samples were sterile-
filtered (0.22µm) and stored at 4°C. The purified IgGs were
analyzed using SDS–PAGE under non-reducing and reducing
conditions as well as analytical gel filtration (on Superdex 200
10/300 GL with an AKTA prime system, GE Healthcare) in
order to estimate aggregate contents and potential contaminants.
Coomassie Blue-stained gels indicated that the IgGs, whatever
the mutations, had >95% purity and displayed the characteris-
tic heavy and light chain bands. Purified IgGs were considered
suitable for biological tests when aggregate rates were below
5%. Limulus Amebocyte Lysate (LAL) endotoxin test Gel Clot
method was further used to test purified IgGs for the presence
of endotoxins. Endotoxin levels of the purified IgGs were below
7 UI/mg.
FcRn BINDING OF IgG VARIANTS BY SURFACE PLASMON RESONANCE
The interaction of IgG variants produced in Y2B/0 with immo-
bilized recombinant human FcRn was monitored by surface plas-
mon resonance (SPR) detection on a BIAcore X100 instrument
using a CM5 sensor chip (BIAcore, GE Healthcare), as previously
described (41). All measurements were performed at 25°C with
IgG concentrations ranging from 1 to 200 nM at a flow rate of
10µl/min. IgGs were diluted in PBS/Tween-20 (50 mM sodium
phosphate, pH 6.0, 150 mM NaCl, 0.02% NaN3, 0.01% Tween-20),
which is used as running buffer in equilibrium binding experi-
ments. Data were collected for 10 min and a 1 min pulse of PBS,
pH 8.0 containing 0.05% Tween-20 was used to regenerate sur-
faces. The equilibrium RU observed for each injection was plotted
against the IgG concentration. The equilibrium K D values were
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determined using the steady-state affinity model included in the
BIA evaluation software version 3.1.
ADCC ACTIVITY
Human natural killer cells (NK cells) were purified from the
peripheral blood of healthy volunteer donors by the negative
depletion technique developed by Miltenyi. The ADCC test com-
prises incubating the NK cells with CD20-expressing Raji target
cells, in the presence of different concentrations of anti-CD20 anti-
bodies. After 16 h of incubation, the cytotoxicity induced by the
anti-CD20 antibodies was measured by quantifying in cell super-
natants the level of the intracellular enzyme lactate dehydrogenase
(LDH) released from lysed target cells. The specific lysis results are
expressed as the percentage of lysis as a function of antibody con-
centration. EC50 values (antibody concentration inducing 50% of
maximum lysis induced by the IgG-WT) and Emax (percentage
of maximum lysis) were calculated using the software GraphPad
PRISM.
CDC ACTIVITY
The CD20-expressing Raji target cells were incubated with differ-
ent concentrations of anti-CD20 antibodies (0–5,000 ng/ml) in the
presence of baby rabbit serum as a source of complement (Cedar-
lane, dilution to 1/10). After 1 h of incubation at 37°C, the level
of LDH released in the supernatant by the lysed target cells was
measured chromogenically (Roche Applied Sciences Cytotoxicity
Detection Kit) and used to quantify the complement-dependent
cytotoxicity mediated by the antibodies. The results were expressed
as a percentage of lysis. EC50 (quantity of antibody that induces
50% of maximum lysis) and Emax (percentage of maximum lysis)
were calculated using the software GraphPad PRISM.
PRODUCTION OF IgG VARIANTS IN HEK293-F CELLS
The Fc WT and variants were cloned into the eukaryotic expres-
sion vector pMGM05-CD20 as a BamHI/Not I fragment using
standard PCR protocols. The pMGM05-CD20 vector is derived
from pCEP4 (Invitrogen) and contains the heavy chain of the
anti-CD20 antibody previously expressed in Y2B/0 cells [based
on the Fv domain of CAT 13.6E12 (50)]. The light chain of this
antibody was inserted into a similar vector derived from pCEP4
(pMGM01-CD20). FreeStyle™ HEK293-F cells (Invitrogen), cul-
tured in 24-well plates, were co-transfected with pMGM01-CD20
and pMGM05-CD20 vectors (Fc-WT and variants) in equimo-
lar amounts (250 ng/ml) with FreeStyle™ MAX reagent (1µl/ml)
using standard protocols (Invitrogen). Cells were cultured in sus-
pension in serum-free medium for 7 days post-transfection and
supernatants (1 ml) containing IgG were harvested after centrifu-
gation of the cells at 100 g for 10 min. IgG secreted in the super-
natants were quantified using an ELISA assay on recombinant
protein L (Pierce), with purified anti-CD20 antibody produced
in HEK293-F cells used as standard. Supernatants and standard
antibody, serially diluted in PBS/0.05% Tween-20, were tested on
Maxisorp immunoplates (Nunc) previously coated with 0.25µg
protein L/well and blocked with 5% skimmed milk in PBS. After
incubation for 1 h at 37°C, wells were washed three times with
PBS/0.05% Tween-20. Bound IgG variants were detected with an
HRP goat anti-human IgG (γ chain specific) F(ab′)2 fragment
(Sigma). IgG variants produced were quantified (1–4µg/ml) using
the standard curve.
ELISA TESTS OF IgG VARIANTS PRODUCED IN THE SUPERNATANTS OF
HEK293-F CELLS
The IgG variants were tested for their binding to the human
complement C1q and several human Fc receptors by ELISA: C1q
complement (Calbiochem), FcγRIIIA-V158 (R&D system), FcRn-
p3, FcγRIIA-R131 (R&D system), and FcγRIIB (R&D system).
ELISA tests were performed in PBS for all effector molecules except
for FcRn, which was realized in P6. Maxisorp immunoplates were
coated with 0.5µg C1q complement/well in PBS, 0.1µg FcγRIIIA-
V158/well in PBS, or 0.1µg FcRn-p3/well in P6. Immobilizer
nickel chelate plates (Nunc) were coated with 0.1µg FcγRIIA-
R131/well or 0.4µg FcγRIIB/well in 0.01 M KCl. After coating
overnight at 4°C, plates were washed two times with PBS/0.05%
Tween-20 (or P6/0.05% Tween-20 for FcRn) and saturated with
PBS/4% BSA (or P6/4% BSA for FcRn) for 2 h at 37°C. In parallel,
supernatants were diluted in PBS to a final IgG concentration of
0.5µg/ml (or diluted in P6 to 0.3µg/ml for the FcRn-binding test)
and mixed with HRP F(ab′)2 goat anti-human F(ab′)2 at the same
concentration for 2 h at room temperature. F(ab′)2-aggregated
IgGs were then incubated under gentle agitation for 1 h at 30°C
on the saturated ELISA plates without dilution for C1q, FcγRIIA-
R131, and FcγRIIB (i.e., IgGs at 0.5µg/ml), diluted in PBS to
0.25µg/ml for FcγRIIIA-V158 or diluted in P6 to 0.0375µg/ml
for FcRn-p3. Plates were then revealed with TMB (Pierce) and
absorbance read at 450 nm.
RESULTS
RANDOMMUTAGENESIS TO INCREASE FcRn BINDING
Use of MutaGen™ and phage display technologies
The human IgG1 Fc gene encoding amino acid residues 226–
447 (referred to as Fc-WT, for Fc Wild Type) was cloned into
our modified phagemid vector (51). This Fc-WT molecule com-
prises the five most C-terminal amino acids of the hinge region
and the entire CH2 and CH3 domains. In our previous study
(41), several fully randomized libraries were generated using low
fidelity human DNA polymerases to introduce random muta-
tions homogeneously throughout the entire gene without any
hot spot (MutaGen™ technology). Fc variants with improved
FcRn binding were then isolated from these Fc-libraries using a
pH-dependent phage display selection on human recombinant
FcRn. Briefly, FcRn binding and washing steps were performed
at pH 6.0 whereas bound Fc-phages were eluted at pH 7.4 to
preserve Fc/FcRn interaction pH dependency, which is crucial
for its physiological role. Two successive rounds of mutagenesis
and selection (called MS1 and MS2) were performed to cumu-
late Fc mutations with a positive impact on Fc/FcRn interac-
tion. Thus, for the MS2 step, the DNA template used to con-
struct random libraries was a DNA pool of 42 variants with
improved FcRn binding by phage-ELISA selected during the MS1
step.
Throughout MS1 and MS2 rounds, 500 Fc variants were iso-
lated and ranked according to their FcRn-binding properties using
a comparative phage-ELISA assay at pH 6.0. To set up this exper-
iment, the double variant T250Q/M428L (Fc-QL) (17) and the
triple mutant M252Y/S254T/T256E (Fc-YTE) (15) were con-
structed as positive controls. In this phage-ELISA assay (at pH
6.0) on human recombinant FcRn, the Fc-QL, and Fc-YTE con-
trol variants, expressed on the M13 bacteriophage, had a specific
Frontiers in Immunology | Immunotherapies and Vaccines February 2015 | Volume 6 | Article 39 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Monnet et al. IgG variants with increased FcRn binding
signal threefold stronger than the Fc-WT (average ratio of 3.2
for Fc-QL and 3.5 for Fc-YTE). As expected, none of the control
variants Fc-QL and Fc-YTE nor the Fc-WT showed any bind-
ing at pH 7.4 (data not shown). During the MS1 round, a total
of 227 different Fc variants were isolated, 139 were considered
positive with a ratio/Fc-WT >2 and 73 were better than the pos-
itive control Fc-QL (ratio/Fc-WT >3.2). The best clone, S5A-41,
had a ratio/Fc-WT of 9.0. During the MS2 round, 223 differ-
ent mutated clones were isolated. Since the difference between
the signals of the Fc-WT and the Fc variants was too great
to be directly compared, these variants were ranked using a
comparative phage-ELISA assay against the Fc-QL variant as ref-
erence. The best Fc variant isolated during MS1, S5A-41, was
used as positive control on each phage-ELISA plate, its ratio/Fc-
QL was 3.9 (±0.6). Among the 223 Fc variants tested, 209 Fc
variants were better than the Fc-QL and 39 Fc variants were
Table 1 | Characterization of Fc variants isolated during the MS2
process.
Fc
variants
Mutations Ratio/
Fc-QL
SD
C6A-69 T307A/N315D/A330V/E382V/N389T/N434Y 8.9 1.7
C6A-78 T256N/A378V7S383N/N434Y 8.7 1.9
T5A-74 N315D/A330V/N361D/A378V/N434Y 8.6 1.6
C6A-74 V259I/N315D/N434Y 8.5 1.5
C6A-60 P230S/N315D/M428L/N434Y 8.4 1.8
T5A-58 F241L/V264E/T307P/A378V/H433R 8.1 1.5
C6A-72 T250A/N389K/N434Y 8.0 1.1
T5A-93 V305A/N315D/A330V/P395A/N434Y 8.0 1.6
T5A-78 V264E/Q386R/P396L/N434S/K439R 8.0 1.5
T5A-87 N315D/A330V/O362R/N434Y 7.8 1.4
C6A-66 E294del/T307P/N434Y 7.7 0.9
C6A-85 V305A/N315D/A330V/N389K/N434Y 7.4 1.5
C8A-15 N315D/A327V/A330VA/397M/N434Y 7.4 1.8
T5A-89 P230T/F241L/V264E/D265G/A378V/N421T 7.1 1.2
T7A-92 V264E/P396L/S415N/N434S 6.7 1.5
T6A-57 P227L/V264E/A378V/N434S 6.4 1.7
T5A-94 V264E/A378T/P396L 5.8 1.0
T6A-75 P230T/N315D/Q362R/S426T/N434Y 5.7 1.3
C3A-13 C226G/N315D/A330V/N434Y 5.6 0.9
T5A-55 P230L/F241L/F243L/V264E/T307P/A378V 5.6 1.2
S5A-41 P230T/V303A/K322R/N389T/F404L/N434S 3.9 0.6
T6A-21 N315D/A378V/N434Y 3.1 0.5
T4A-04 N315D/A330V/E382V/N434Y 3.0 0.1
C3A-01 N315D/A330V/N434Y 2.5 0.1
C3A-03 N315D/N434Y 2.0 0.4
C6A-05 T307A/N315D/A330V/N434Y 1.9 0.4
M3A-01 N361D/N434Y 1.4 0.1
Mutations and phage-ELISA ratios obtained for the 20 best Fc variants of MS2
compared with the positive control Fc-QL (upper part of the Table). The six vari-
ants chosen to be further characterized are in bold. Below the S5A-41 variant are
listed the Fc variants that were characterized during MS2 and are combinations
of two to four mutations also found in our six preferred variants (lower part of the
table).
better than the S5A-41 variant. Sequences and phage-ELISA results
obtained for the 20 best Fc variants from MS2 in compari-
son with the S5A-41 variant are detailed in the upper part of
Table 1. To compare the variants from MS2 with the variants
from MS1, an estimated ratio/Fc-WT was calculated by mul-
tiplying the ratio/Fc-QL of the variants with the ratio/Fc-WT
of the Fc-QL (=3.2± 0.3) determined during MS1 (ratio/Fc-
WT= 3.2× ratio/Fc-QL). Using this calculation, the S5A-41 vari-
ant had a ratio/Fc-WT of 12.5 instead of 9.0 when tested directly
in comparison with the Fc-WT during the MS1. Ranking of sig-
nificant Fc variants from MS1 and MS2 using this calculation is
illustrated in Table 2.
Table 2 | Comparison of Fc variants selected during MS1 and MS2.
Fc
variants
Mutations Ratio/
Fc-WT
Variant
origin
C6A-69 T307A/N315D/A330V/E382V/
N389T/N434Y
28.4 MS2
C6A-78 T256N/A378V/S383N/N434Y 27.8 MS2
C6A-78A T256N/A378V/N434Y 27.8 MS2+
mutagenesis
T5A-74 N315D/A330V/N361D/A378V/
N434Y
27.6 MS2
C6A-74 V259I/N315D/N434Y 27.2 MS2
C6A-60 P230S/N315D/M428L/N434Y 26.8 MS2
C6A-66 E294del/T307P/N434Y 24.6 MS2
T6A-21 N315D/A378V/N434Y 10.0 MS2
T4A-04 N315D/A330V/E382V/N434Y 9.6 MS2
S5A-41 P230T/V303A/K322R/N389T/ 9.0 MS1
F404L/N434S (12.5)
C3A-01 N315D/A330V/N434Y 8.0 MS2
C3A-03 N315D/N434Y 6.4 MS2
C6A-05 T307A/N315D/A330V/N434Y 6.1 MS2
S4A-02 A378V/N434Y 4.6 MS1
M3A-01 N361D/N434Y 4.5 MS2
L6B-41 P230S/M428L 4.4 MS1
S4A-11 N389T/N434Y 3.7 MS1
S3A-35 N434Y 3.5 MS1
B4A-13 P228L 3.5 MS1
B3A-32 P228R 3.1 MS1
B5A-35 P230S 2.8 MS1
S3A-05 N434S 2.7 MS1
B4A-22A A378V 2.6 MS1+
mutagenesis
B5A-25B N315D 2.1 MS1+
mutagenesis
B5A-15 M428L 2.0 MS1
S3A-25A V264E 1.9 MS1+
mutagenesis
L3A-01 T256N 1.8 MS1
B3A-17 T307A 1.3 MS1
Mutations and phage-ELISA ratios obtained in comparison with the Fc-WT. Analy-
sis of the single mutations and the different combinations of mutations allowed
us to ascertain the impact of the mutations included in our six preferred variants.
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Data mining using results from random mutagenesis and
phage-ELISA
Given the high number of positive clones isolated, a data base
was constructed to store and analyze the DNA sequences and the
phage-ELISA results obtained for the Fc variants isolated during
MS1 and MS2 processes. Sequence analysis of the positive Fc vari-
ants (i.e., variants with a ratio/Fc-WT >2, corresponding to 139
variants from MS1 and 219 variants from MS2) identified the fol-
lowing 9 key positions, which are positions mutated in more than
10% of the improved Fc variants: P230, F241, V264, T307, N315,
A330, A378, N389, and N434. Remarkably, the position N434 is
mutated in almost 80% of the positive variants, whereas positions
V264, N315, and A378 are mutated in more than 40% of the pos-
itive variants (41). These findings are clearly noticeable for the 20
best Fc variants listed in Table 1, which all comprise 2–3 key posi-
tions combined with 1–3 other mutations (4.45 mutated amino
acids on average). From our Fc variants, we chose the five best vari-
ants (C6A-69, C6A-78, T5A-74, C6A-74, and C6A-60) as well as
the C6A-66 variant for more thorough characterization (in bold
in Tables 1 and 2). The latter was selected for its originality to
contain an amino acid deletion (E294Del). Data mining from our
data base showed that many Fc variants isolated from MS1 and
MS2 were combinations of one to four mutations also found in
our six selected variants (six Fc variants from MS2, lower part of
Table 1 and Fc variants from MS1 and MS2 assembled in Table 2).
This allowed us to verify by comparison if each mutation included
in our six selected variants had a real positive effect on the FcRn
binding. In case that no appropriate variant for comparison was
available, new variants were generated by directed mutagenesis to
reveal the impact of associated mutations. The resulting variants
were named as the parental clone with a letter added at the end of
the name (Table 2).
The C6A-60 variant comprises four mutations (P230S/N315D/
M428L/N434Y) each of which is present as single mutations in the
Fc variants B5A-35 (P230S), B5A-25B (N315D), B5A-15 (M428L),
and S3A-35 (N434Y) and where they had a direct impact on FcRn
binding, with ratios/Fc-WT ranging from 2 to 3.5 each. The C6A-
60 variant is also a combination of the two double variants L6B-41
(P230S/M428L) and C3A-03 (N315D/N434Y), which both dis-
play additive effects of the single mutations (ratios/Fc-WT of 4.4
and 6.4, respectively). Conversely, the final combination of the 4
mutations, C6A-60 exhibits synergistic effects with a ratio/Fc-WT
>25, instead of 10–15 in case of additive effects of the muta-
tions. The C6A-74 variant comprises the double variant C3A-03
(N315D/N434Y) as well, with the addition of one mutation,V259I
that was never seen in another Fc variant but has a great impact
on Fc/FcRn binding, increasing the ratio/Fc-WT from 6.4 to more
than 25. The T5A-74 variant is composed of five mutations, three
of which have been tested as single mutations in the Fc variants
B5A-25B (N315D), B4A-22A (A378V), and S3A-35 (N434Y) and
have demonstrated a positive impact on Fc/FcRn interaction. The
impact of the N361D mutation is confirmed by comparison of
the variants M3A-01 (N361D/N434Y) and S3A-35 (N434Y). Like-
wise, the contribution of the A330V mutation is confirmed by
comparison of the variants C3A-03 (N315D/N434Y) and C3A-
01 (N315D/A330V/N434Y). The C6A-78 variant comprises four
mutations, three of which exert a positive effect as shown in
the variants L3A-01 (T256N), B4A-22A (A378V), and S3A-35
(N434Y). The last mutation, N383S, was not included in any other
variant and its removal, C6A-78A variant, seems to have no effect
on FcRn binding. This mutation was therefore identified as unnec-
essary to improve FcRn binding. This result was confirmed by
SPR with purified IgG variants (Table 4) and, therefefore, C6A-78
variant was replaced by C6A-78A in the subsequent tests. Finally,
the C6A-69 variant includes six mutations, three of which were
shown to have a positive effect in the mutation variants B3A-17
(T307A), B5A-25B (N315D), and S3A-35 (N434Y). The impact
of the A330V was described above for the T5A-74 variant. The
comparison of the S4A-11 (N389T/N434Y) and S3A-35 (N434Y)
variants suggests a modest contribution for the N389T mutation
that needs to be confirmed. The impact of the E382V mutation is
confirmed by comparison of the C3A-01 (N315D/A330V/N434Y)
and T4A-04 (N315D/A330V/E382V/N434Y) variants.
Overall, these data permitted to confirm the direct contribu-
tion of most of the key positions identified previously by sequence
analyses: P230, T307, N315, A330, A378, and N434. Moreover,
the key position V264E, which is not found in our six best vari-
ants, was also tested as a single mutation, and a ratio/Fc-WT
of 1.9 was obtained. Interestingly, these analyses also permitted
the identification of a position in the hinge region, P228 that
induces a significant FcRn binding increase when mutated to L or
R (ratio/Fc-WT of 3.5 and 3.1, respectively). This position was not
identified as a key position but displays the strongest FcRn bind-
ing increase as a single mutation, similarly to the crucial position
N434, mutated to Y or S (ratio/Fc-WT of 3.5 and 2.7, respectively).
Distribution of the identified mutations on the Fc sequence
The amino acids previously identified were visualized on a 3D
representation of the IgG1 Fc fragment modeled using crystallo-
graphic data (52) and Discovery Studio software (positions in red
sticks, right panel of Figure 1). In parallel, the residues that have
been involved in the Fc/FcRn interaction by crystallography (14)
and directed mutagenesis (13, 53) were positioned on an analo-
gous 3D representation. The FcRn-binding site encompasses three
distinct zones in the Fc fragment at the interface between the CH2
and CH3 domains: residues 252–254, 307–311 in the CH2 domain,
and residues 433–436 in the CH3 domain (positions in purple
ribbon, left panel of Figure 1). Using this structural knowledge,
several Fc variants with increased FcRn affinity have been obtained
by alanine scanning (13), directed mutagenesis (15, 21), and in sil-
ico approaches (16–18) albeit focusing on the FcRn-binding site.
These optimized Fc variants, developed by other groups, mainly
include the residues T250, M252, S254, T256, V259, T307, V308,
M428, H433, and N434 (positions in purple sticks, left panel of
Figure 1), all located inside the FcRn-binding site. In contrast,
the random mutagenesis method used to generate our Fc vari-
ants allowed to identify positions distributed over the whole Fc
region. Among the positions identified, two are directly in the
FcRn-binding site, one in the CH2 domain (T307), and the other
in the CH3 domain (N434) and have been largely described pre-
viously (13, 18, 20). Three positions are close to the FcRn-binding
site, one in the CH2 domain (N315), and the two others (A378
and N389) in the CH3 domain. Finally, five positions are located
outside the FcRn-binding site: P228 and P230 in the lower hinge
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FIGURE 1 | 3D representation of a model of the Fc fragment
from the human IgG1 made with Discovery Studio software.
The last five amino acids of the hinge region are in yellow. The CH2
domain is in green and the CH3 domain is in blue. Left panel: in
purple, the FcRn-binding site in the CH2–CH3 interdomain region,
with the main positions used by others to increase FcRn binding
highlighted: T250, M252, S254, T256, V259, T307, M428, H433, and
N434. Right panel: the key positions identified in our study are
highlighted in red. These mutations are distributed over the entire
Fc sequence.
region and F241, V264, and A330 in the upper part of the CH2
domain. The mutations identified on these positions probably
have a positive long-range effect on the overall structure of the
Fc domain favoring the Fc/FcRn complex.
DIRECTED MUTAGENESIS TO INCREASE FcRn BINDING
Unexpectedly, the use of random mutagenesis and phage display
selection revealed the contribution of mutations located in the
Fc hinge domain on Fc/FcRn binding (P228R or L and P230S).
Since these mutations were rarely used in our optimized vari-
ants, we combined them with our five best variants C6A-69,
C6A-78A, T5A-74, C6A-74, and C6A-60 in an attempt to fur-
ther increase their FcRn binding. New variants were constructed
using directed mutagenesis by adding in the hinge region one
or two mutations as follow: P230S, P228L, P228R, P228L/P230S,
or P228R/P230S. These new variants were named based on the
parental variant with a letter added at the end of the name (A–
G) (Table 3). They were tested using phage-ELISA assay at pH
6.0 and result of each new variant was directly compared to its
parental molecule to estimate the influence of the added muta-
tion(s) (ratio new variant/parental variant). Depending on the
parental variant, the results observed were very heterogeneous
as the mutations displayed unpredictable and sometimes oppo-
site effects. For instance, the mutation P228L could either have
a negative (C6A-69 and C6A-60), a neutral (T5A-74), or a mod-
est positive effect (C6A-78 and C6A-74). The mutations P230S,
P228L/P230S, and P228R/P230S had mostly negative or neutral
effects, with the exception of the combination of P228R/P230S
with T5A-74 (twofold increase). Finally, the mutation P228R was
the most efficient mutation with a neutral effect on two variants
(C6A-69 and C6A-60) and a positive effect on three variants (C6A-
78, T5A-74, and C6A-74), with ratios ranging from 2.2- to 3.3-fold
increase compared to the parental molecule. These results exem-
plify the difficulty of designing optimized variants by directed
mutagenesis, the resulting effect of the combination of several
positive mutations being often unpredictable.
Successful combinations based on the parental variant C6A-
78 were selected to be further characterized. IgG-WT and variants
C6A-78, C6A-78A, C6A-78B, and C6A-78D were produced as full-
length IgGs with the variable regions of the chimeric anti-human
CD20 CAT 13.6E12 in Y2B/0 cells as described before (41). FcRn
affinities of these IgGs were measured by SPR on immobilized
recombinant human FcRn at pH 6.0 (Table 4). In this assay, the
K D values of the four IgG variants ranged from 19.8 to 33.1 nM
as compared to 101.0 nM for the IgG-WT. This experiment con-
firmed that the C6A-78A variant has a similar affinity as C6A-78,
albeit having one mutation less (N383S) and that the C6A-78B
variant displays a slightly increased affinity. However, the positive
impact of the mutation P228R (C6A-78D) was not confirmed. In
the IgG molecule, this position P228 may be more constrained
than in the phage display system, impeding the substitution by the
arginine, whereas the substitution by the leucine seems to conserve
a positive impact.
IMPACT OF MUTATIONS INCREASING FcRn BINDING ON EFFECTOR
FUNCTIONS
IgG variants produced in Y2B/0 cells
Together with the IgG-WT and the four IgG variants described
above, IgG-YTE and the selected variants C6A-69, T5A-74, C6A-
74, C6A-60, and C6A-66 were also produced as full-length IgGs
with the variable regions of the chimeric anti-human CD20
CAT 13.6E12 (50). To combine the advantages of glyco- and
protein-Fc engineering, these IgGs variants were produced in
YB2/0 cells (EMABling® platform), permitting low fucosylation
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Table 3 | Comparison of Fc variants generated by directed
mutagenesis to increase FcRn binding.
Fc
variants
Mutations Ratio
variant/
parental
variant
SD
C6A-69E P228R/C6A-69 1.1 0.3
C6A-69 T307A/N315D/A330V/E382V/N389T/N434Y 1.0 0.2
C6A-69C P230S/C6A-69 0.9 0.1
C6A-69D P228L/C6A-69 0.5 0.1
C6A-78D P228R/C6A-78A 3.3 0.8
C6A-78B P228L/C6A-78A 1.7 0.2
C6A-78F P228R/P230S/C6A-78A 1.1 0.2
C6A-78C P230S/C6A-78A 1.1 0.3
C6A-78A T256N/A378V/N434Y 1.0 0.1
C6A-78E P228L/P230S/C6A-78A 0.7 0.0
T5A-74D P228R/T5A-74 3.0 0.7
T5A-74F P228R/P230S/T5A-74 2.0 0.6
T5A-74 N315D/A330V/N361D/A378V/N434Y 1.0 0.2
T5A-74C P228L/T5A-74 0.9 0.2
T5A-74E P228L/P230S/T5A-74 0.8 0.2
T5A-74B P230S/T5A-74 0.7 0.2
C6A-74D P228R/C6A-74 2.2 0.5
C6A-74C P228L/C6A-74 1.3 0.3
C6A-74E P228L/P230S/C6A-74 1.0 0.3
C6A-74 V259I/N315D/N434Y 1.0 0.2
C6A-74F P228R/P230S/C6A-74 0.9 0.2
C6A-74A P230S/C6A-74 0.7 0.1
C6A-60 P230S/N315D/M428L/N434Y 1.0 0.2
C6A-60D P228R/C6A-60 0.9 0.2
C6A-60C P228L/C6A-60 0.6 0.2
The positions in the hinge domain (P228 and P230) identified by random muta-
genesis were combined with our five best variants using directed mutagenesis
and resulted in further increased FcRn binding in phage-ELISA assays.
of the IgG glycan moiety resulting in enhanced ADCC as previ-
ously described for two antibodies in clinical development, the
anti-CD20 mAb ublituximab (54–56), and the anti-RhD mAb
roledumab (57, 58). All such produced IgG variants conserved the
same antigen binding properties as the IgG-WT and contain ~35%
of fucosylated glyco-forms (data not shown). As described above,
SPR measures on immobilized FcRn confirmed the increased FcRn
affinity for all our IgG variants (41). IgGs were then tested for
their capacity to elicit ADCC with purified NK cells against CD20-
expressing target cells (Table 5, left column). As described before
(41), our five best IgG variants displayed similarly high ADCC as
the IgG-WT showing that they all have retained glyco-engineered
improved ADCC activity. A slightly increased ADCC was even
observed for the IgG variants C6A-74 and C6A-60 (x3.7 and x6.7,
respectively). On the other hand, the C6A-66 variant, which con-
tains the deletion of the amino acid E294, has completely lost
ADCC activity. The C6A-78 and C6A-78A, differing from one
mutation (N383S) that was confirmed to be dispensable for FcRn
Table 4 | SPR affinity measures at steady state on immobilized
recombinant human FcRn of IgG-WT and variants produced inYB2/0
cells.
IgG variants Mutations KD (nM) Ratio KD
WT/variant
WT None 101.0 1.0
C6A-78 T256N/A378V/S383/N434Y 33.1 3.1
C6A-78A T256N/A378V/N434Y 26.1 3.9
C6A-78B P228L/T256N/A378V/N434Y 19.8 5.1
C6A-78D P228R/T256N/A378V/N434Y 25.3 4.0
Table 5 | ADCC and CDC results of IgG-WT and IgG variants produced
inYB2/0 cells.
IgG
variants
Mutations ADCC:
ratio EC50
WT/variant
CDC: ratio
EC50 WT/
variant
C6A-69 T307A/N315D/A330V/E382V/N389T/
N434Y
2.6 < 0.1
C6A-78 T256N/A378V/S383N/N434Y 1.3 5.6
C6A-78A T256N/A378V/N434Y 1.1 5.9
C6A-78B P228L7T256N/A378V/N434Y 0.7 9.1
C6A-78D P228R/T256N/A378V/N434Y 0.4 7.7
T5A-74 N315D/A330V/N361D/A378V/N434Y 1.8 < 0.1
C6A-74 V259l/N315D/N434Y 6.7 1.2
C6A-60 P230S/N315D/M428L/N434Y 3.7 5.6
C6A-66 E294Del/T307P/N434Y <0.1 0.6
YTE M252Y/S254T/T256E 0.2 <0.1
Results are expressed as ratio EC50 WT/variant. Increased ratios therefore corre-
spond to an improved ADCC or CDC activity of the IgG variant compared to the
IgG-WT.
0–0.7; 0.7–2 ; 2–10 .
affinity, displayed similar ADCC. On contrary, the addition of
mutations on position P228 seems to decrease ADCC, especially
when arginine is used (C6A-78B and C6A-78D, x0.7 and 0.4,
respectively, compared to a ratio of 1.1 for C6A-78). Interest-
ingly, the IgG-YTE variant, despite being mutated exclusively in
the FcRn-binding site, has lost its ADCC activity.
Immunoglobulins G were also tested for their ability to induce
CDC activity against CD20-expressing target cells in presence of
baby rabbit serum (Table 5, right column). The level of CDC
activity varies between IgG variants. C6A-78, C6A-78A, C6A-78B,
C6A-78D, and C6A-60 variants have a CDC activity significantly
higher than that of IgG-WT whereas C6A-69, T5A-74, and C6A-66
displayed low CDC activity. The CDC activity of C6A-74 variant
is similar to that of IgG-WT. Moreover, the IgG-YTE variant has
also lost CDC activity.
Overall, these results show that the selected variants for
increased FcRn binding have different ADCC and CDC activi-
ties. One variant, C6A-60, has increased ADCC and CDC and
one variant, C6A-74, has increased ADCC and conserved CDC.
Two variants, C6A-69 and T5A-74, have conserved ADCC and low
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CDC. Two variants, C6A-78 and C6A-78A, have conserved ADCC
and increased CDC. Two variants, C6A-78B and C6A-78D, have
decreased ADCC and increased CDC. Finally, one variant (C6A-
66) has lost both ADCC and CDC activities, a feature also observed
for the positive control IgG-YTE.
IgG variants produced in HEK cells
Using the same antigen specificity as previously described, IgG-
WT and variants were expressed in HEK293-F cells, a classical
cell line, which produces IgGs with high fucose content (80–90%)
resulting in low ADCC as compared to IgGs produced in YB2/0
cells. To rapidly compare numerous variants for their binding
properties to several Fc effectors (C1q, FcγRIIIA-V158, FcγRIIA-
R131, and FcγRIIB and FcRn), IgGs were produced in small
quantities (1 ml), titrated in cell supernatants, and directly tested
by ELISA. Results for each receptor were expressed as a ratio of
specific signal obtained for the IgG variant compared to the signal
of the IgG-WT (Table 6). Our six previously selected IgG vari-
ants were tested thereby, with eight new improved combinations
based on the results obtained by phage-ELISA (Table 3). Several
positive controls were produced as well to set up the experiments.
For FcRn, we used the IgG-QL and IgG-YTE variants described
above but also the double variant M428L/N434S (Fc-LS) (18). The
positive control for FcγRIIIA was S239D/I332E (C1) (38), for the
complement C1q; K326W/E333S (C3) (47), for FcγRIIA; G236A
(C4) (48), and for FcγRIIB; S267E/L328F (C5) (49). Results for
the positive controls C1–C5 are in agreement with published and
patented data (US 2009/0042291 A1 and EP2386574 A2), validat-
ing our experimental setting. The C1 variant has increased binding
for the three FcγRs tested. The C3 and C4 variants are selectively
improved for one receptor each, the complement C1q and the
FcγRIIA, respectively. The C5 variant binding is largely improved
for FcγRIIB but also FcγRIIA-R131. As expected, the three positive
controls IgG-LS, -QL, and -YTE display increased FcRn-binding
ability (ratios 4.46, 2.39, and 2.06, respectively). All our improved
IgG variants demonstrate similar increase (ratios between 2.83 and
4.72), with no significant differences. This ELISA assay was not
discriminant enough to reveal potential slight differences between
the variants for their FcRn binding. Interestingly, the IgG-YTE
demonstrated a decreased binding capacity to the complement
C1q and to the three FcγRs tested, in correlation with the func-
tional results obtained with IgGs produced in YB2/0 cells (Table 5).
Our variants display diverse binding patterns: selective decrease
for FcγRIIIA (C6A-60), decrease for all the receptors (C6A-66,
C6A-69, and C6A-69E), no change for any receptor (C6A-74, C6A-
74C, and C6A-74D), slight increase for all the receptors (C6A-78,
Table 6 | Binding cartography of IgG variants produced in HEK293 cells on the complement C1q, FcγRIIIA-V158, FcγRIIA-R131, FcγRIIB, and FcRn.
IgG variants Mutations ELISA: ratio variant/WT
C1q SD FcγRlllaV SD FcγRllaR SD FcγRllb SD FcRn SD
C1 S239D/I332E 0.80 0.20 7.85 3.04 5.77 1.55 5.69 3.15 1.02 0.12
C3 K326W/E333S >30.00 ND 0.55 0.18 1.09 0.71 1.17 0.28 1.25 0.29
C4 G236A 0.68 0.14 0.65 0.17 9.06 3.71 1.64 0.78 1.01 0.13
C5 S267E/L328F 4.40 1.36 0.36 0.18 10.20 1.42 24.59 4.25 0.62 0.10
Fc-LS M428L/N434S 2.39 0.49 1.30 0.32 2.52 0.18 0.97 0.04 4.46 0.29
Fc-QL T250Q/M428L 2.47 0.46 0.59 0.08 0.99 0.21 0.95 0.10 2.39 0.82
Fc-YTE M252Y/S254T/T256E 0.64 0.15 0.27 0.03 0.27 0.06 0.42 0.01 2.06 0.59
C6A-69 T307A/N315D/A330V/E382V/N389T/N434Y 0.58 0.09 0.65 0.13 0.43 0.05 0.55 0.04 3.67 1.06
C6A-69E P228R/C6A-69 0.46 0.10 0.67 0.17 0.40 0.03 0.55 0.06 4.40 1.23
C6A-78 T256N/A378V/S383N/N434Y 2.22 0.75 1.88 0.31 3.15 0.65 2.46 0.72 4.10 0.88
C6A-78A T256N/A378V/N434Y 4.02 0.21 2.38 0.34 2.82 0.57 2.62 0.40 4.72 0.92
C6A-78B P228L/C6A-78A 1.93 0.21 1.73 0.04 2.27 0.30 2.09 0.29 4.29 0.60
C6A-78D P228R/C6A-78A 1.90 0.01 2.01 0.28 2.19 0.70 1.86 0.05 4.40 0.98
T5A-74 N315D/A330V/N361D/A378V/N434Y 0.49 0.08 1.77 0.46 0.90 0.31 0.74 0.45 3.50 0.48
T5A-74D P228R/T5A-74 0.50 0.07 2.16 0.56 0.79 0.29 1.11 0.50 3.33 0.86
T5A-74F P228R/P230S/T5A-74 0.48 0.17 0.74 0.26 0.58 0.43 0.91 0.59 3.73 0.84
C6A-74 V259I/N315D/N434Y 1.16 0.13 1.09 0.13 1.31 0.15 1.18 0.19 2.83 0.72
C6A-74C P228L/C6A-74 0.95 0.13 0.89 0.06 1.14 0.13 1.34 0.19 3.03 0.78
C6A-74D P228R/C6A-74 0.87 0.11 1.02 0.10 1.05 0.05 1.30 0.06 3.48 0.88
C6A-60 P230S/N315D/M428L/N434Y 1.05 0.22 0.47 0.08 1.34 0.25 0.88 0.07 3.76 0.82
C6A-66 E294Del/T307P/N434Y 0.55 0.20 0.08 0.03 0.12 0.07 0.36 0.17 4.41 0.98
Results are expressed as ratio variant/WT. Increased ratios therefore correspond to improved binding on to the receptor as shown by ELISA assay.
0–0.7; 0.7–2 ; 2–10 ; >10 .
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C6A-78A, C6A-78B, and C6A-78D), and decrease for the com-
plement C1q binding (T5A-74, T5A-74D, and T5A-74F). The
complement C1q binding results are in good correlation with the
CDC results obtained with IgGs produced in YB2/0 cells. Con-
versely, FcγRIIIA binding results are significantly different from
the ADCC results previously obtained (Table 5). For instance,
C6A-60 and C6A-74, which displayed increased ADCC as low-
fucose molecules, demonstrate decreased or conserved FcγRIIIA
binding, respectively, when produced in HEK293 cells. Altogether,
in accordance to what we observed for the IgG molecules pro-
duced in Y2B/0 cells, these results show that the variants selected
for increased FcRn binding exhibit different binding patterns to
the complement C1q and the FcγRs.
DISCUSSION
Due to the remarkable role of FcRn in IgG serum persistence,
the Fc/FcRn interactions have been comprehensively studied at
the molecular level by mutagenesis (13, 53) and crystallography
(59) using mice, rat, and human FcRn. The FcRn-binding site is
highly conserved among species and comprises residues located
at the CH2/CH3 domains interface: residues 252–254, 307, and
309–311 in the CH2 domain, and residues 433–436 in the CH3
domain. Moreover, for the human Fc/FcRn interaction, the pH
dependence has been attributed to the histidine residues H310 and
H435, involved in salt bridges with acidic FcRn residues. Various
human Fc variants with improved FcRn affinity, and conserved
pH dependence, were designed using this structural knowledge
and resulted in increased serum half-life. For instance, residues
250 and 428, which are close to the CH2/CH3 interface, were tar-
geted by mutagenesis permitting the isolation of the double variant
T250Q/M428L (Fc-QL), exhibiting a ~27-fold binding improve-
ment on human FcRn expressed on the cell surface (16,17). In silico
analysis was also used to design several variants combining muta-
tions in or close to the FcRn-binding site. Two of these variants,
M428L/N434S (IgG-LS, Xtend) and V259I/V308F/M428L (IgG-
IFL), showed a ~11- and ~20-fold improved binding to human
FcRn by SPR, respectively, resulting in approximately four- to
fivefold half-life extension in cynomolgus monkeys and three-
fold half-life extension in hFcRn-transgenic mice (18). On the
other hand, the triple variant M252Y/S254T/T256E (IgG-YTE)
was obtained by phage display selection against murine FcRn of
rationally designed libraries targeting Fc residues in or close to the
FcRn-binding site (residues 251–256, 308–314, 385–389, and 428–
436) (15). When introduced in an anti-RSV and an anti-IL6 IgG1,
these YTE mutations increased the IgG binding to human FcRn
by about 10-fold by SPR, resulting in a nearly fourfold increase in
serum half-life in cynomolgus monkeys (23, 60). Importantly, the
anti-RSV YTE variant (motavizumab) resulted in up to fourfold
longer half-life in healthy humans, confirming for the first time
in humans the concept of half-life extension using Fc-engineered
antibodies (26). Interestingly, when the crystal structure of the
Fc-YTE mutant (residues 236–444) was compared to its WT coun-
terpart, very few structural changes were observed. Therefore, the
greatly enhanced interaction between Fc-YTE and human FcRn is
likely mediated by local effects at the substitutions sites (61, 62).
Without using this structural knowledge of Fc/FcRn interac-
tion, we previously identified several mutations in the Fc region,
which increase FcRn-binding capacity using a fully random
mutagenesis approach combined with a pH-dependent selection
process by phage display (41). The use of two successive rounds
of random mutagenesis and selection directly allowed finding
optimized variants, partly because of synergistic effects of the dif-
ferent mutations. The effect of several of these mutations was
unpredictable by rational design as the mutated positions were
located distantly from the FcRn-binding site, for example, P228
and P230 in the hinge domain and F241, V264, and A330 in the
CH2 domain, and have not been previously described. Neverthe-
less, the best variants isolated included at least one mutation in
the FcRn-binding site (mostly N434S or N434Y). In this study,
we used data obtained from random mutagenesis, and from new
variants constructed by directed mutagenesis, to verify whether
each mutation included in our best variants has indeed a positive
effect on the FcRn-binding capacity. Indeed, a minor disadvan-
tage of random mutagenesis is that dispensable mutations could
be simultaneously selected and need to be identified afterwards.
For one variant only (C6A-78), we identified one mutation that
had no effect on FcRn binding (N383S). This result indicates that
dispensable mutations are infrequently selected using our system,
most of the selected mutations being important for FcRn-binding
improvement. Besides, because three single mutations with the
greatest FcRn binding were unexpectedly located in the hinge
domain (P228L, P228R, and P230S), we cumulated them with our
best variants in an attempt to further increase FcRn binding. Sur-
prisingly, additive or neutral effects were observed depending on
the parental variant these mutations were added to. These results
suggest that designing optimized variants by directed mutagene-
sis is not straightforward as unpredictable results can be obtained
when combining several positive mutations. However, several such
rationally designed variants showed further increased FcRn bind-
ing by phage-ELISA. When two of these variants were produced
as full IgG molecules, C6A-78B (C6A-78/P228L) and C6A-78D
(C6A-78/P288R), only the first molecule displayed a modest affin-
ity increase by SPR. This discrepancy could be due to the use
of different techniques to measure FcRn-binding. SPR on puri-
fied IgG molecules is certainly the most accurate technique but
could be less discriminant than the phage-ELISA technique. FcRn-
binding improvement up to 28-fold was obtained by phage-ELISA
whereas by SPR the best variant showed a 7.4-fold binding increase
(41). Alternatively, the discrepancy observed could arise from the
phage display system itself. In this system, the Fc fragment is fused
to the N-terminal part of the M13 bacteriophage pIII coat pro-
tein. Hence, the N-terminal part of the Fc fragment (226–447)
is exposed at the phage surface. The position P228 could be less
constrained than in the IgG molecule, favoring the replacement by
the arginine, while the substitution by the leucine could conserve
a positive impact in both systems.
Despite the potential limitations of the phage display system,
we and others have clearly shown the advantages of using this sys-
tem for the selection of engineered Fcs with modulated binding to
FcRn (15). In this system, the Fc fragment is aglycosylated but the
Fc/FcRn interaction is not dependent on the Fc glycosylation site
occupancy (2). Most importantly, the use of the phage display sys-
tem enables the use of an in vitro selection procedure based on the
pH dependency of the Fc/FcRn interaction, a specific feature that
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is critical to preserve. Indeed, increased affinity at high pH could be
problematic by preventing the release of FcRn-bound IgGs. Aug-
mented clearance was consequently observed for IgG engineered
for improved FcRn affinity at both pH 6.0 and pH 7.4, where pH
dependence is reduced (63). Furthermore, recent studies empha-
sized the difficulty of conserving the pH dependency because when
a variant’s affinity to FcRn is increased at pH 6.0, its binding
at higher pH increases accordingly (21, 64). Several mutations
demonstrating a slight increase in FcRn binding at pH 7.4 were
described, among which M252Y and N434Y. Yet, these mutations
are included in variants with increased serum half-life (IgG-YTE
and our Fc variants, respectively), suggesting that combinations
of several mutations could result in different pH dependency or
that this parameter is not sufficient to predict half-life modula-
tion. Owing to the difficultly of assessing and interpreting the pH
dependence, IgG variants with increased FcRn binding are usually
assayed for half-life extension in cynomolgus monkeys and/or in
hFcRn mice. These FcRn-humanized mice, unlike wild-type mice,
have been shown to be a reliable surrogate for studying human IgG
serum half-life (20, 65, 66). Indeed, human and murine FcRn have
significant molecular differences, especially concerning pH depen-
dency, rendering wild-type mice an inadequate model for studying
half-life of engineered human IgGs (67–70). In these hFcRn mice,
several Fc-engineered variants showed equivalent half-life increase
(~3-fold), despite distinct affinity improvements, suggesting that
Fc engineering may have reached a plateau for FcRn improvement
designed to increase half-life (18, 20). Likewise, our best Fc vari-
ants administered to hFcRn showed extended half-life, ranging
from 1.8- to 2.8-fold increase (41). Most of the variants described
herein were not tested in hFcRn mice and we cannot predict their
behavior in vivo.
A great advantage of the fully random mutagenesis approach
used is that identified mutations are distributed all over the length
of the Fc region, potentially having an impact on all effector func-
tions. We indeed showed that these FcRn optimized Fc variants
display diverse binding capacities to the complement C1q and the
FcγRs, resulting in modulated effector activities with increased,
conserved, or decreased ADCC and/or CDC activities. Because
these activities are essential for the therapeutic efficacy of mAbs,
our studies were not limited to one but several Fc variants, which
were stored and documented in a database, providing us with dis-
tinct “fit-for-purpose” Fc molecules. This database now includes
more than 1500 molecules with diverse binding properties. The
optimal Fc properties of a given therapeutic mAb are adjustable
and will depend on the antibody mode of action (agonistic, cyto-
toxic, blocking. . .), and on the antigen and pathology targeted.
MAbs can trigger a variety of effects by engaging the comple-
ment C1q and different FcγRs expressed by immune cells thus
the adequate binding profile for a given molecule needs to be
defined. Besides, ADCC activity has been clearly associated with
the therapeutic efficacy of mAbs in oncology, but many ques-
tions remain concerning the respective roles of ADCC, CDC,
and ADCP activities. For other therapeutic applications, like for
instance, for anti-viral antibodies, the importance of Fc-dependent
effector functions was established for mAbs against several infec-
tious pathogens including HIV (71), RSV (72), and Ebola virus
(73). Therefore, many protein-Fc-engineered mAbs with increased
binding to FcγRIIIA and/or FcγRIIA (37, 38, 48) but also to the
complement C1q (47, 74) have been designed in an attempt to
enhance therapeutic efficacy and several such engineered mAbs are
now in clinical trials (75, 76). Besides, glyco-engineered mAbs with
enhanced ADCC due to low or afucosylation are now used clin-
ically (40). We previously showed that such a glyco-engineering
technology, LFB’s EMABling® platform, can be combined with
protein-Fc engineering to increase half-life (41). Indeed, when
produced in YB2/0 cells, permitting low-fucose content in the
Fc glycan moiety, most of our IgG variants conserved improved
ADCC, in correlation with FcγRIIIA binding. In contrast, when
produced in HEK293 cells, a cell line classically resulting in high
fucose content, FcγRIIIA binding results were significantly dif-
ferent from the ADCC results previously obtained. These results
suggest that glyco- and Fc-protein engineering can elicit non-
compatible effects, resulting in different ADCC activities depend-
ing on the production cell line. This divergence between cell lines
was not observed when CDC activities and complement C1q bind-
ing were compared. This was expected as fucosylation, which is
known to have no influence on this effector property.
Finally, the C6A-66 variant showed poor binding to the com-
plement C1q and all FcγRs as well as loss of ADCC and CDC
activities. These characteristics are probably due to an unusual
deletion of one amino acid, located in position 294. Nonethe-
less, this variant could be of great interest as for certain clinical
applications no effector function could be preferable and, for this
variant,ADCC and CDC are completely abolished while half-life is
largely enhanced (77). For example, many anti-cytokine mAbs are
currently developed as IgG4 or IgG2 mAbs because they display
lower effector functions (1, 78, 79), such mAbs could be developed
with our C6A-66 variant. The IgG-YTE positive control showed
similarly reduced effector activities and decreased binding to the
complement C1q and to all FcγRs. The reduced ADCC activity of
this variant has been observed before and was restored by addition
of mutations S239D/A330L/I332E, known to strongly enhance
FcγRIIIA binding (60). We show here that producing the IgG-YTE
variant as a low fucosylated molecule cannot restore ADCC activ-
ity. Overall, the results obtained for the YTE variant are surprising
since this variant comprises three mutations M252Y/S254T/T256E
located exclusively in the FcRn-binding site, as clearly observed by
crystallography (61). It is noteworthy that C1q and the FcγRs
bind to a region involving the hinge and the hinge-proximal por-
tion of the CH2 domain. This region is distant from the CH2/CH3
domain interface containing the residues implicated in FcRn bind-
ing. Since mutations at the FcRn-binding site seem to have a great
impact on FcγRs and C1q binding as well, these binding sites can-
not be considered as independent just because of their relative
distant localization. We therefore provide evidence that half-life
and effector functions should be optimized simultaneously. Com-
prehensive understanding of these interactions will not only allow
for development of effective therapeutics but also avoidance of
potential adverse effects.
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